The Board of directors of Natco Pharma have approved the proposal for buy-back of its own fully paid-up equity shares of face value of Rs 2 each for an aggregate amount not exceeding Rs 2500 Millions.
Natco Pharma consolidated net profit rises 115.17% in the September 2018 quarter
08 - Nov - 2018 12:00 AM | 9 days ago
Net profit of Natco Pharma rose 115.17% to Rs 181.60 crore in the quarter ended September 2018 as against Rs 84.40 crore during the previous quarter ended September 2017. Sales rose 27.37% to Rs 543.50 crore in the quarter ended September 2018 as against Rs 426.70 crore during the previous quarter ended September 2017.
Natco Pharma standalone net profit rises 120.94% in the September 2018 quarter
05 - Nov - 2018 12:00 AM | 12 days ago
Net profit of Natco Pharma rose 120.94% to Rs 193.10 crore in the quarter ended September 2018 as against Rs 87.40 crore during the previous quarter ended September 2017. Sales rose 27.91% to Rs 522.40 crore in the quarter ended September 2018 as against Rs 408.40 crore during the previous quarter ended September 2017.
Natco Pharma announced that its Board of directors have approved buy-back of fully paid equity shares of Face value Rs 2 each at a price not exceeding Rs 1000 equity share for an aggregate amount not exceeding Rs 2500 Mn through open market route.
